Skip to main content
TipRanks
Go Ultimate75% OFF

Summit Therapeutics (SMMT) Stock Statistics & Valuation Metrics

2,046 Followers

Total Valuation

Summit Therapeutics has a market cap or net worth of $11.32B. The enterprise value is $12.89B.

Market Cap
$11.32B
Enterprise Value
$12.89B

Share Statistics

Summit Therapeutics has 799,763,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
799,763,900
Owned by Insiders
―
Owned by Institutions
―

Financial Efficiency

Summit Therapeutics’s return on equity (ROE) is -1.64 and return on invested capital (ROIC) is -160.56%.

Return on Equity (ROE)
-1.64
Return on Assets (ROA)
-1.44
Return on Invested Capital (ROIC)
-160.56%
Return on Capital Employed (ROCE)
-1.61
Revenue Per Employee
0
Profits Per Employee
-4.07M
Employee Count
265
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Summit Therapeutics is -13.22. Summit Therapeutics’s PEG ratio is 28.77.

PE Ratio
-13.22
PS Ratio
0.00
PB Ratio
20.00
Price to FCF
-21.41
Price to Operating Cash Flow
-21.49
PEG Ratio
28.77

Income Statement

In the last 12 months, Summit Therapeutics had revenue of 0 and earned -1.08B in profits. Earnings per share was -1.44.

Revenue
0
Gross Profit
0
Operating Income
-1.09B
Pretax Income
-1.08B
Net Income
-1.08B
EBITDA
-1.08B
Earnings Per Share (EPS)
-1.44

Cash Flow

In the last 12 months, operating cash flow was -525.54M and capital expenditures -1.73M, giving a free cash flow of -527.27M billion.

Operating Cash Flow
-525.54M
Free Cash Flow
-527.27M
Free Cash Flow per Share
-0.66

Dividends & Yields

Summit Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-5.59%
Earnings Yield
-8.83%

Stock Price Statistics

Beta
1.80
52-Week Price Change
-22.51%
50-Day Moving Average
16.41
200-Day Moving Average
16.20
Relative Strength Index (RSI)
42.16
Average Volume (3m)
6.17M

Important Dates

Summit Therapeutics upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 04, 2026
Next Earnings Date
Mar 18, 2027
Ex-Dividend Date
―

Financial Position

Summit Therapeutics as a current ratio of 9.87, with Debt / Equity ratio of 3.17%

Current Ratio
9.87
Quick Ratio
9.87
Debt to Market Cap
0.00
Net Debt to EBITDA
0.19
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Summit Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Summit Therapeutics EV to EBITDA ratio is -11.17, with an EV/FCF ratio of -17.64.

EV to Sales
0.00
EV to EBITDA
-11.17
EV to Free Cash Flow
-17.64
EV to Operating Cash Flow
-17.69

Balance Sheet

Summit Therapeutics has $629.79M in cash and marketable securities with $19.98M in debt, giving a net cash position of $609.80M billion.

Cash & Marketable Securities
$629.79M
Total Debt
$19.98M
Net Cash
$609.80M
Net Cash Per Share
$0.76
Tangible Book Value Per Share
$0.70

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Summit Therapeutics is $28.08, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$28.08
Price Target Upside
98.46% Upside
Analyst Consensus
Moderate Buy
Analyst Count
13
Revenue Growth Forecast
―
EPS Growth Forecast
13.96%

Scores

Smart Score
2
AI Score
49